Biogen Inc. Files 8-K on Financials
Ticker: BIIB · Form: 8-K · Filed: Oct 14, 2025 · CIK: 875045
| Field | Detail |
|---|---|
| Company | Biogen Inc. (BIIB) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0005, $2 million, $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, sec-filing
Related Tickers: BIIB
TL;DR
Biogen filed an 8-K on Oct 14, 2025, detailing financial results. Check it out.
AI Summary
Biogen Inc. filed an 8-K on October 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. Biogen Inc. is incorporated in Delaware and headquartered at 225 Binney Street, Cambridge, Massachusetts.
Why It Matters
This filing provides investors with updated information on Biogen's financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information.
Key Players & Entities
- BIOGEN INC. (company) — Filer
- 225 BINNEY STREET (location) — Business Address
- CAMBRIDGE (location) — City
- MA (location) — State
- 02142 (location) — ZIP Code
- October 14, 2025 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K filing?
The filing is categorized under 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', indicating a report on the company's financial performance.
When was this 8-K report filed with the SEC?
The report was filed on October 14, 2025.
What is the principal executive office address for Biogen Inc.?
The principal executive offices are located at 225 Binney Street, Cambridge, Massachusetts, 02142.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is Biogen Inc.'s state of incorporation and IRS Employer Identification Number?
Biogen Inc. is incorporated in Delaware and its IRS Employer Identification Number is 33-0112644.
Filing Stats: 987 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2025-10-14 16:19:10
Key Financial Figures
- $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select
- $2 million — and milestone expense of approximately $2 million on a pre-tax basis. The estimated charg
- $0.01 — he third quarter 2025 by approximately ($0.01) per share. During the first quarter
Filing Documents
- biib-20251014.htm (8-K) — 27KB
- biib-20251014_g1.jpg (GRAPHIC) — 3KB
- 0000875045-25-000040.txt ( ) — 201KB
- biib-20251014.xsd (EX-101.SCH) — 2KB
- biib-20251014_lab.xml (EX-101.LAB) — 21KB
- biib-20251014_pre.xml (EX-101.PRE) — 24KB
- biib-20251014_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the third quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $2 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the third quarter 2025 by approximately ($0.01) per share. During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development. Biogen does not forecast such acquired in-process research and development, upfront and milestone expense due to the uncertainty of the future occurrence, magnitude and timing of these transactions in any given period. Results for the quarter ended September 30, 2025, have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from the preliminary unaudited estimates described herein. Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements relating to our financial and operating results and financial guidance, that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the "Safe Harbor" provisions of the PSLRA. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate,"
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biogen Inc. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: October 14, 2025